Navigation Links
Genova files patent for new prostate cancer treatment
Date:9/8/2009

NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

The peptide, called Prostaganin, is a 21-amino compound which is highly reactive to prostate cancer cells, and has the ability to specifically target them. In laboratory experiments, Prostaganin has demonstrated an ability to preferentially bind to and disrupt certain negatively charged components of the membranes of prostate cancer cells.

Prostaganin thus has tremendous potential as a superior new form of treating prostate cancer. Current treatment methods such as surgery, radiation and chemotherapy are outmoded, unsatisfactory, and have severe side effects. Prostaganin offers a positive alternative. The peptide, bio-engineered from naturally occurring compounds in the human body, can target and destroy cancerous cells, whilst leaving surrounding healthy tissues intact, and causing no undesirable side effects. Further development of this novel peptide could revolutionize the way people fight cancer.

The demand for new and better treatments for prostate cancer has never been higher. Prostate cancer presently accounts for 30% of all the major cancers in men. The Prostate Cancer Foundation states that prostate cancer is the cancer with the largest expected increase in the next decade, and that annual incidence of the cancer will rise to 300,000 cases in the U.S. alone by 2015.

"Prostaginin represents a significant milestone in GENova's business agenda to acquire patents for the most innovative new cancer treatments," says Aaron Whiteman, CEO of GENova, "But most importantly, it represents a new generation of cancer treatments that could save millions of lives, and treat prostate cancer in men with no side effects or adverse effects on quality of life. The implications are tremendous." Licensing to companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec could prove to be extremely lucrative in the short and long term. GENova works very hard on a daily basis to close agreements with big Biotechnology players in the industry.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies. Visit GENova online at www.genovabio.comForward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova names Dr. John Savin as Vice President
2. GENova names Aaron Whiteman as CEO
3. Sun Pharmaceutical Files HSR Application for Taro Tender Offer
4. InfoLogix Files Preliminary Proxy Statement in Connection with Special Meeting of Its Stockholders to Approve Recapitalization Plan
5. VirtualHealth Technologies Files 8k Related to the August 17th Announcement of Private Access Payment and Document Modification
6. Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning
7. "Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing
8. AMDL Inc. Files Notification of Late Filing for Form 10-Q
9. Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches
10. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
11. Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... that offers insurance and financial preparation services, is providing an update on a ... organization. , Rock City Rescue is a locally recognized nonprofit that provides shelter ...
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology: